- Home
- ACET
ACET
Adicet Bio Inc.
as 07-26-2024 4:00pm EST
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its lead preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
| Founded: | 1947 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 124.1M | IPO Year: | N/A |
| Target Price: | $14.20 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.94 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.05 - $3.77 | Next Earning Date: | 08-07-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 87.53% |
Stock Insider Trading Activity of Adicet Bio Inc. (ACET)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Kauffman Michael | ACET | Director | Jun 5 '24 | Sell | $1.43 | 5,900 | $8,437.00 | 5,900 | SEC Form 4 |
| GORDON CARL L | ACET | Director10% Owner | Jan 25 '24 | Buy | $2.40 | 1,841,100 | $4,418,640.00 | 7,526,359 | SEC Form 4 |
| GORDON CARL L | ACET | Director10% Owner | Jan 25 '24 | Buy | $2.40 | 242,200 | $581,280.00 | 990,254 | SEC Form 4 |
| GORDON CARL L | ACET | Director10% Owner | Jan 25 '24 | Buy | $2.40 | 1,041,700 | $2,500,080.00 | 1,255,985 | SEC Form 4 |
Latest Adicet Bio Inc. News
ACET Breaking Stock News: Dive into ACET Ticker-Specific Updates for Smart Investing
Insider Monkey
2 days ago
Why Is Adicet Bio, Inc. (ACET) a Good One-Dollar Stock to Buy According to Hedge Funds?
Simply Wall St.
4 days ago
Owning 44% shares,institutional owners seem interested in Adicet Bio, Inc. (NASDAQ:ACET),
Business Wire
19 days ago
Adicet Bio Receives FDA Fast Track Designation for ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma
Business Wire
a month ago
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Business Wire
a month ago
Adicet Bio Announces FDA Clearance of IND Application for ADI-270 in Renal Cell Carcinoma
Insider Monkey
a month ago
Is Adicet Bio, Inc. (NASDAQ:ACET) the Best Halal Stock ?
Simply Wall St.
2 months ago
We're Keeping An Eye On Adicet Bio's (NASDAQ:ACET) Cash Burn Rate
Business Wire
2 months ago
Engelhart Commodities Trading Partners Agrees to Acquire Trailstone, Strengthening Commitment to the Energy Transition
Compare ACET vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ACET Adicet Bio Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.